Form 4: Ted Kellner Acquires Shares of AIM ImmunoTech Inc.

Director Ted Kellner reports acquisition of AIM ImmunoTech shares through direct purchase and indirect holdings via various entities.

Summary

• Ted Kellner, a director of AIM ImmunoTech Inc., reported changes in beneficial ownership.
• On April 11, 2025, Kellner purchased 1,968,504 shares of common stock at a price of $0.0254 per share.
• These shares were acquired pursuant to a purchase agreement executed on April 11, 2025, but required approval from the NYSE American, which was received on April 21, 2025.
• Kellner also indirectly owns 1,456,000 shares through Kelvest I LP, where he serves as Manager of T&M Partners LLC, the General Partner.
• Additionally, he indirectly owns 270,000 shares through the Beta Fund Investment Club, where he is the manager and an investor, and 25,000 shares through the Kellner, Ted Combined Profit Sharing/Money Purchase Plan, where he serves as trustee.
• The report amends a prior Form 3 filed on December 23, 2024, due to a restructuring of family entities effective April 1, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports a transaction. The director's purchase could be interpreted positively, but without further context, it's difficult to gauge the overall impact.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in the biotechnology industry. Monitoring such filings can provide insights into management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director may increase investor confidence.

Key Dates

Keywords

AIM ImmunoTech, beneficial ownership, Form 4, Ted Kellner, share acquisition, director